Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

C921-78: a new factor Xa antagonist prevents thrombosis with reduced blood loss

Nov. 12, 1997

Fibrinogen receptor occupancy, antiplatelet activity and safety of lefradafiban

Nov. 10, 1997

Lamifiban efficacy demonstrated in PARAGON trial

Nov. 10, 1997

Preclinical and clinical profile of Searle's fibrinogen antagonist

Nov. 10, 1997

TP-9201 covered by new U.S. patent

Nov. 10, 1997

Fibrinogen antagonists from Merck & Co.

Nov. 10, 1997

Spotlight on thrombin inhibitors

Nov. 10, 1997

ReoPro cleared in U.S. for expanded labeling

Nov. 7, 1997

Saruplase efficacy demonstrated in large patient study

Nov. 7, 1997

PEG-hirudin compared to established antithrombotic agents

Nov. 7, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 8, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 8, 2024.
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
BioWorld
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.